Contributors: University of Birmingham Birmingham; Princess Máxima Center for Pediatric Oncology; Universität Bern / University of Bern (UNIBE); Université de Lausanne = University of Lausanne (UNIL); Saint Anna Children's Hospital Vienne = St Anna Kinderspital (St. Anna Children's Hospital); University of Linz - Johannes Kepler Universität Linz (JKU); IRCCS Istituto Giannina Gaslini Genoa, Italy; Danish Cancer Society Research Center Copenhagen, Denmark (DCSRC); Landspitali National University Hospital of Iceland; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle University Newcastle; Université de Lucerne = Universität Luzern (UNILU); Oslo University Hospital Oslo; Università degli Studi di Milano-Bicocca = University of Milano-Bicocca (UNIMIB); University Medical Centre Ljubljana Ljubljana, Slovenia (UMCL); Radboud University Medical Center Nijmegen; Skane University Hospital Lund; Università degli studi di Torino = University of Turin (UNITO); Azienda Ospedalerio - Universitaria Città della Salute e della Scienza di Torino = University Hospital Città della Salute e della Scienza di Torino; Centre de recherche en épidémiologie et santé des populations (CESP); Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay; Institut Gustave Roussy (IGR); Johannes Gutenberg - Universität Mainz = Johannes Gutenberg University (JGU); Semmelweis University Budapest; Cancer Registry of Norway; IRCCS Istituto Nazionale dei Tumori Milano; Institute of Oncology Ljubljana; Bern University Hospital Berne (Inselspital); Emma Children’s Hospital; University of Turku; Aarhus University Aarhus; Pfizer; Compagnia di San Paolo, CSP; Seventh Framework Programme, FP7: 257505; Irish Association for Cancer Research, IACR; University of Birmingham; CHILDREN with CANCER UK: 20457; Agence Nationale de la Recherche, ANR; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, SNF; Javna Agencija za Raziskovalno Dejavnost RS, ARRS; Krebsliga Schweiz: KLS‐3412‐02‐2014, KLS‐3886‐02‐2016, KLS‐5432‐08‐2021; KWF Kankerbestrijding, DCS: DCOG2011‐5027, UVA2012‐5517; Associazione Italiana per la Ricerca sul Cancro, AIRC; Institut National Du Cancer, INCa; Swiss Cancer Research Foundation: KFS‐02783‐02‐2011, KFS‐4157‐02‐2017, KFS‐4722‐02‐2019, KFS‐5302‐02‐2021, KLA/KFS‐4825‐01‐2019; The authors are very grateful to the childhood cancer survivors whose information was used in this data set. The authors thank the following individuals from each country for their contribution to data preparation: Angela Jackson, Florent Dayet, Amar Kahlouche, Fara Diop, Sylvie Challeton, Martine Labbé, and Isao Kobayashi; the Italian Association of Pediatric Hematology and Oncology–Off Therapy Registry Group, Maura Massimino, Silvia Caruso, Monica Muraca, Vera Morsellino, Claudia Casella, Lucia Miligi, Anita Andreano, Andrea Biondi, and the Italian Association of Cancer Registries Working Group; Dutch Childhood Oncology Group LATER, Wim Tissing, Marry van den Heuvel‐Eibrink, Eline van Dulmen, Dorine Bresters, and Birgitta Versluys; Tina Žagar; Ingemar Andersson and Susanne Nordenfelt; Elisabeth Kiraly, Vera Mitter, Shelagh Redmond, and the Swiss Pediatric Oncology Group ( www.spog.ch ); Julie Kelly. Author Isabelle M. Dudley also thanks the Arthur Thomson Trust at the University of Birmingham for their financial support and interest in this project. The PanCareSurFup consortium and related work was supported by the European Union’s Seventh Framework Programme for research, technological development, and demonstration under grant agreement no. 257505. Additional financial support was received from: the Foundation Force de Recherche sur le Cancer de l’Enfant, The Italian Association for Cancer Research and the Compagnia San Paolo, the Fondo Chiara Rama ONLUS, the Swedish Childhood Cancer Fund, the French Association for Cancer Research, the French National Agency for Research (Hope‐Epi project), the French National Cancer Institute, Pfizer Foundation for Children and Adolescent Health, the Slovenian Research Agency, the Swiss Paediatric Oncology Group, the Swiss Cancer League (KLS‐3412‐02‐2014, KLS‐3886‐02‐2016, and KLS‐5432‐08‐2021), the Swiss Cancer Research Foundation (KFS‐02783‐02‐2011, KFS‐4157‐02‐2017, KLA/KFS‐4825‐01‐2019, KFS‐4722‐02‐2019, and KFS‐5302‐02‐2021), the Swiss National Science Foundation (PDFMP3_141775), the Dutch Cancer Society (DCOG2011‐5027 and UVA2012‐5517), the Norwegian Childhood Cancer Foundation, and Children with Cancer UK (grant no: 20457). France: Italy: Netherlands: Slovenia: Sweden: Switzerland: United Kingdom; The authors are very grateful to the childhood cancer survivors whose information was used in this data set. The authors thank the following individuals from each country for their contribution to data preparation: France: Angela Jackson, Florent Dayet, Amar Kahlouche, Fara Diop, Sylvie Challeton, Martine Labbé, and Isao Kobayashi; Italy: the Italian Association of Pediatric Hematology and Oncology–Off Therapy Registry Group, Maura Massimino, Silvia Caruso, Monica Muraca, Vera Morsellino, Claudia Casella, Lucia Miligi, Anita Andreano, Andrea Biondi, and the Italian Association of Cancer Registries Working Group; Netherlands: Dutch Childhood Oncology Group LATER, Wim Tissing, Marry van den Heuvel-Eibrink, Eline van Dulmen, Dorine Bresters, and Birgitta Versluys; Slovenia: Tina Žagar; Sweden: Ingemar Andersson and Susanne Nordenfelt; Switzerland: Elisabeth Kiraly, Vera Mitter, Shelagh Redmond, and the Swiss Pediatric Oncology Group (www.spog.ch); United Kingdom: Julie Kelly. Author Isabelle M. Dudley also thanks the Arthur Thomson Trust at the University of Birmingham for their financial support and interest in this project. The PanCareSurFup consortium and related work was supported by the European Union’s Seventh Framework Programme for research, technological development, and demonstration under grant agreement no. 257505. Additional financial support was received from: the Foundation Force de Recherche sur le Cancer de l’Enfant, The Italian Association for Cancer Research and the Compagnia San Paolo, the Fondo Chiara Rama ONLUS, the Swedish Childhood Cancer Fund, the French Association for Cancer Research, the French National Agency for Research (Hope-Epi project), the French National Cancer Institute, Pfizer Foundation for Children and Adolescent Health, the Slovenian Research Agency, the Swiss Paediatric Oncology Group, the Swiss Cancer League (KLS-3412-02-2014, KLS-3886-02-2016, and KLS-5432-08-2021), the Swiss Cancer Research Foundation (KFS-02783-02-2011, KFS-4157-02-2017, KLA/KFS-4825-01-2019, KFS-4722-02-2019, and KFS-5302-02-2021), the Swiss National Science Foundation (PDFMP3_141775), the Dutch Cancer Society (DCOG2011-5027 and UVA2012-5517), the Norwegian Childhood Cancer Foundation, and Children with Cancer UK (grant no: 20457).
نبذة مختصرة : International audience ; Background: Survivors of Hodgkin lymphoma (HL) are at risk of developing non-Hodgkin lymphoma (NHL) after treatment; however, the risks of developing subsequent primary lymphomas (SPLs), including HL and NHL, after different types of childhood cancer are unknown. The authors quantified the risk of SPLs using the largest cohort of childhood cancer survivors worldwide. Methods: The Pan-European Network for Care of Survivors After Childhood and Adolescent Cancer (PanCare) Survivor Care and Follow-Up Studies (PanCareSurFup) cohort includes 69,460 five-year survivors of childhood cancer, diagnosed during 1940 through 2008, from 12 European countries. Risks of SPLs were quantified by standardized incidence ratios (SIRs) and relative risks (RRs) using multivariable Poisson regression. Results: Overall, 140 SPLs, including 104 NHLs and 36 HLs, were identified. Survivors were at 60% increased risk of an SPL compared with the general population (SIR, 1.6; 95% confidence interval [CI], 1.4–1.9). Survivors were twice as likely to develop NHL (SIR, 2.3; 95% CI, 1.9–2.8), with the greatest risks among survivors of HL (SIR, 7.1; 95% CI, 5.1–10.0), Wilms tumor (SIR, 3.1; 95% CI, 1.7–5.7), leukemia (SIR, 2.8; 95% CI, 1.8–4.4), and bone sarcoma (SIR, 2.7; 95% CI, 1.4–5.4). Treatment with chemotherapy for any cancer doubled the RR of NHL (RR, 2.1; 95% CI, 1.2–3.9), but treatment with radiotherapy did not (RR, 1.2; 95% CI, 0.7–2.0). Survivors were at similar risk of developing a subsequent HL as the general population (SIR, 1.1; 95% CI, 0.8–1.5). Conclusions: In addition to HL, the authors show here for the first time that survivors of Wilms tumor, leukemia, and bone sarcoma are at risk of NHL. Survivors and health care professionals should be aware of the risk of NHL in these survivors and in any survivors treated with chemotherapy.
Processing Request
No Comments.